Table 1.
Characteristics of the study cohort.
| Overall | PVI | Uninfected | |
|---|---|---|---|
| N = 176 | N = 32 (18.2%) |
N = 144 (81.8%) |
|
| Sex | |||
| Female | 123 (69.9%) | 17 (53.1%) | 106 (73.6%) |
| Male | 53 (30.1%) | 15 (46.9%) | 38 (26.4%) |
| Race | |||
| White | 125 (71.0%) | 20 (62.5%) | 105 (72.9%) |
| Black | 23 (13.1%) | 7 (21.9%) | 16 (11.1%) |
| Asian | 16 (9.1%) | 2 (6.2%) | 14 (9.7%) |
| Others | 8 (4.5%) | 3 (9.4%) | 5 (3.5%) |
| Not reported | 4 (2.3%) | 0 (0%) | 4 (2.8%) |
| Ethnicity | |||
| Non-Hispanic | 163 (92.6%) | 31 (96.9%) | 132 (91.7%) |
| Hispanic | 10 (5.7%) | 1 (3.1%) | 9 (6.2%) |
| Not reported | 3 (1.7%) | 0 (0%) | 3 (2.1%) |
| Occupation | |||
| Nurse | 52 (29.5%) | 8 (25.0%) | 44 (30.6%) |
| Physician | 49 (27.8%) | 5 (15.6%) | 44 (30.6%) |
| Physical/occupational/recreational therapist | 25 (14.2%) | 6 (18.8%) | 19 (13.2%) |
| Other staff | 21 (11.9%) | 3 (9.4%) | 18 (12.5%) |
| Lab personnel | 11 (6.3%) | 3 (9.4%) | 8 (5.5%) |
| Medical technician | 6 (3.4%) | 4 (12.5%) | 2 (1.4%) |
| Psychologist | 6 (3.4%) | 1 (3.1%) | 5 (3.5%) |
| Social worker | 5 (2.8%) | 2 (6.2%) | 3 (2.1%) |
| Not reported | 1 (0.6%) | 0 (0%) | 1 (0.6%) |
| Age | |||
| 18–44 | 96 (54.5%) | 16 (50.0%) | 80 (55.5%) |
| 45–64 | 75 (42.6%) | 16 (50.0%) | 59 (41.0%) |
| 65+ | 5 (2.9%) | 0 (0%) | 5 (3.5%) |
| Median age (IQR) | 42.5 (34.0–52.0) | 44.5 (32.8–50.3) | 42.0 (34.0–52.0) |
| Prior infections (hybrid immunity) | |||
| Pre-visit infections | 11 (6.3%) | 1 (3.1%) | 10 (6.9%) |
| Time between prior infection and sample collection | |||
| Median days (IQR) | 350.0 (180.0–361.5) | 350.0 (350.0–350.0) | 339.5 (162.0–365.3) |
| Charlson Comorbidity Index (CCI) | |||
| 0 | 154 (87.5%) | 31 (96.9%) | 123 (85.4%) |
| 1 | 13 (7.4%) | 0 (0%) | 13 (9.0%) |
| 2 | 7 (4.0%) | 1 (3.1%) | 6 (4.2%) |
| 3 | 2 (1.1%) | 0 (0%) | 2 (1.4%) |
| Booster (monovalent) vaccination status | |||
| Boosted (3 doses) | 142 (80.7%) | 24 (75.0%) | 118 (81.9%) |
| Unboosted (2 doses) | 34 (19.3%) | 8 (25.0%) | 26 (18.1%) |
| Time between booster dose and sample collection (boosted group) | |||
| Median days (IQR) | 43.0 (29.0–54.0) | 49.5 (39.8–55.3) | 42.0 (28.3–53.8) |
| Time between 2nd dose and sample collection (unboosted group) | |||
| Median days (IQR) | 285.0 (208.0–303.0) | 195.5 (147.0–292.8) | 290.0 (254.8–308.3) |
| Time between sample collection and post-vaccination infection | |||
| Median days (IQR) | 45.5 (36.5–50.3) | 45.5 (36.5–50.3) | N/A |
PVI, post-vaccine infection; IQR, interquartile range; N/A, non-applicable.